PORCN and breast cancer: In that study, oral administration of Wnt‐c59 was shown to inhibit PORCN activity at nanomolar concentrations, display good bioavailability (i.e., plasma concentrations maintained above the IC50 (i.e., 74 pM) for Wnt‐c59), and attenuate the progression of mammary tumors in mice via the downregulation of Wnt target genes [20].